Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA

International Journal of Cancer

Volumn 131, Issue 11, 2012, Pages 2562-2572

  Piechocki, Marie P ^a   Wu, Gen Sheng ^a   Jones, Richard F ^a   Jacob, Jennifer B ^a   Gibson, Heather ^a   Ethier, Stephen P ^a   Abrams, Judith ^a   Yagita, Hideo ^b   Venuprasad, K ^a   Wei, Wei Zen ^a,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b JUNTENDO UNIVERSITY   (Japan)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antibody; apoptosis; DNA vaccine; DR5 (TRAIL R2); triple negative breast cancer

Indexed keywords

ANTISERUM; CASPASE 3; DEATH RECEPTOR 5; DNA VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AB 631; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ANTIGEN PURIFICATION; APOPTOSIS; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DILUTION; DNA BINDING; DNA CLEAVAGE; DNA CROSS LINKING; DNA ELECTROVACCINATION; DNA IMMUNIZATION; DRUG SENSITIVITY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; ANTIBODIES, NEOPLASM; APOPTOSIS; BALB 3T3 CELLS; BREAST NEOPLASMS; CANCER VACCINES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNE SERA; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MICE; MICE, SCID; NIH 3T3 CELLS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; T-LYMPHOCYTES; VACCINES, DNA;

EID: 84867034026     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27534     Document Type: Article

References (38)

1. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM,. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-37.
2. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA,. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-82.
3. Whittington PJ, Piechocki MP, Heng HH, Jacob JB, Jones RF, Back JB, Wei W-Z,. DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies. Cancer Res 2008; 68: 7502-11.
4. Hampton T,. Novel targeted cancer drugs highlighted. JAMA 2006; 296: 270.
5. Cretney E, Takeda K, Smyth MJ,. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int J Biochem Cell Biol 2007; 39: 280-6.
6. Rowinsky EK,. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 2005; 23: 9394-407.
7. Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE, Sayers TJ, Seki N, Okumura K, Yagita H, Smyth MJ,. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 2004; 199: 437-48.
8. Shi J, Zheng D, Liu Y, Sham MH, Tam P, Farzaneh F, Xu R,. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 2005; 65: 1687-92.
9. Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G, Lenardo MJ, Chan FK,. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA 2005; 102: 18099-104.
10. Wu GS, Burns TF, Zhan Y, Alnemri ES, El-Deiry WS,. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res 1999; 59: 2770-5.
11. Ashkenazi A, Holland P, Eckhardt SG,. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008; 26: 3621-30.
12. Duiker EW, Mom CH, de Jong S, Willemse PH, Gietema JA, van der Zee AG, de Vries EG,. The clinical trail of TRAIL. Eur J Cancer 2006; 42: 2233-40.
13. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG, Ashkenazi A,. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005; 280: 2205-12.
14. Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF, Ashkenazi A, de Vos AM,. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 1999; 4: 563-71.
15. Wassenaar TA, Quax WJ, Mark AE,. The conformation of the extracellular binding domain of death receptor 5 in the presence and absence of the activating ligand TRAIL: a molecular dynamics study. Proteins 2008; 70: 333-43.
16. Natoni A, MacFarlane M, Inoue S, Walewska R, Majid A, Knee D, Stover DR, Dyer MJ, Cohen GM,. TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br J Haematol 2007; 139: 568-77.
17. Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, Meltzer PS, Lipkowitz S,. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 2008; 113: 217-30.
18. Wei WZ, Jacob JB, Zielinski JF, Flynn JC, Shim KD, Alsharabi G, Giraldo AA, Kong YM,. Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice. Cancer Res 2005; 65: 8471-8.
19. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-27.
20. Pai SI, Wu GS, Ozoren N, Wu L, Jen J, Sidransky D, El-Deiry WS,. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 1998; 58: 3513-18.
21. Radkevich-Brown O, Piechocki MP, Back JB, Weise AM, Pilon-Thomas S, Wei WZ,. Intratumoral DNA electroporation induces anti-tumor immunity and tumor regression. Cancer Immunol Immunother 2010; 59: 409-17.
22. Wei WZ, Shi WP, Galy A, Lichlyter D, Hernandez S, Groner B, Heilbrun L, Jones RF,. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 1999; 81: 748-54.
23. Jacob J, Radkevich O, Forni G, Zielinski J, Shim D, Jones RF, Wei W,. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell Immunol 2006; 240: 96-106.
24. Mosmann T,. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
25. Cox DR,. Regression models and life tables (with Discussion). J R Stat Soc B 1972; 34: 187-220.
26. Conover WJ,. Practical nonparametric statistics. New York: Wiley, 1999. 223-36.
27. Mirandola P, Ponti C, Gobbi G, Sponzilli I, Vaccarezza M, Cocco L, Zauli G, Secchiero P, Manzoli FA, Vitale M,. Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood 2004; 104: 2418-24.
28. Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H, Sagolla M, Compaan D, Lowman H, et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 2008; 15: 751-61.
29. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, Zhou T,. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7: 954-60.
30. Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A, Iacobucci A, MacLean M, Lo L, Fox NL, Oza AM,. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008; 14: 3450-5.
31. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, Barrett M, Judson I, Kaye S, Fox NL, Halpern W, Corey A, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007; 13: 6187-94.
32. Thorburn A, Behbakht K, Ford H,. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updat 2008; 11: 17-24.
33. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von GM, Yee SF, Totpal K, Huw L, Katta V, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007; 13: 1070-7.
34. Zhang Y, Zhang B,. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 2008; 6: 1861-71.
35. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T,. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 2003; 22: 2034-44.
36. Jin H, Yang R, Ross J, Fong S, Carano R, Totpal K, Lawrence D, Zheng Z, Koeppen H, Stern H, Schwall R, Ashkenazi A,. Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin Cancer Res 2008; 14: 7733-40.
37. Luster TA, Carrell JA, McCormick K, Sun D, Humphreys R,. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. Mol Cancer Ther 2009; 8: 292-302.
38. Ding Z, Zhou JY, Wei WZ, Baker VV, Wu GS,. Induction of apoptosis by the new anticancer drug XK469 in human ovarian cancer cell lines. Oncogene 2002; 21: 4530-8.